Retinoids increase idarubicin cytotoxicity in human myeloid leukemia cell lines

Anti-Cancer Drugs

Volumn 7, Issue 7, 1996, Pages 774-779

  Tosi, Patrizia ^a   Visani, Giuseppe ^a   Ottaviani, Emanuela ^a   Pellacani, Annalisa ^a   Manfroi, Silvia ^a   Tura, Sante ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute myeloid leukemia; Idarubicin; Retinoids

Indexed keywords

ALITRETINOIN; IDARUBICIN; ISOTRETINOIN; RETINOIC ACID; RETINOID;

ARTICLE; CELL LEVEL; CELL STRAIN HL 60; CELL STRAIN K 562; CELL TYPE; CLONOGENIC ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOFLUOROMETRY; CYTOTOXICITY; DRUG ACCUMULATION; DRUG POTENTIATION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MYELOID LEUKEMIA; PRIORITY JOURNAL;

EID: 0029975787     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199609000-00009     Document Type: Article

References (32)

1. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
2. Dombret H, Scrobohaci ML, Ghorra P, et al. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7: 2-9.
3. Castaigne S, Chomienne C, Daniel MT, Berger R, Fenaux P, Degos L. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-9.
4. Frankel SR, Eardly A, Lauwers G, Weiss M, Warrell RP. The 'retinoic acid syndrome' in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-6.
5. Chen ZY, Xue Q, Zhang R, et al. A clinical and experimental study on all-trans retinoic acid treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-9.
6. Fenaux P, Chastang C, Degos L. Treatment of newly diagnosed acute promyelocytic leukemia (APL) by a combination of all-trans retinoic acid (ATRA) and chemotherapy. Leukemia 1994; 8 (suppl 1): S42-7.
7. Bernard J, Weil M, Boiron M, Jacquillat C, Flandrin G, Gemon MF. Acute promyelocytic leukemia. Results of treatment with daunorubicin. Blood 1973; 41: 489-96.
8. Avvisati G, Mandelli F, Petti MC, et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990; 44: 257-60.
9. Michieli M, Damiani D, Michelutti A, et al. Restoring uptake and retention of daunorubicin and idarubicin in P-170 related multidrug resistance cells by low concentration D-verapamil, cyclosporin-A and SDZ PSC833. Haematologica 1994; 79: 500-7.
10. Anderlini P, Benjamin RS, Wang FC, et al. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. J Clin Oncol 1995; 13: 2827-34.
11. Lo Coco F, Diverio D, Avvisati G, Luciano A, Biondi A, Mandelli F. High frequency of early molecular remission in acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (Italian GIMEMA-AIEOP 'AIDA' trial). Blood 1995; 86: 265a.
12. Yang GS, Minden MD, McCulloch EA. Regulation by retinoic acid and hydrocortisonc of the anthracycline sensitivity of blast cells of acute mycloblastic leukemia. Leukemia 1994; 8: 2065-75.
13. Gallagher R, Collins S, Trujillo J, et al. Characterisation of the continuous differentiating myeloid cell line (HL-60) from a patient with promyelocytic leukemia. Blood 1979; 54: 713-33.
14. Lozzio CB, Lozzio BB. Human chromic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321-7.
15. Momparler RL. In vitro systems for evaluation of combination chemotherapy. Pharmacol Ther 1980; 8: 21-35.
16. Luk C, Tannock IF. Flow cytometric analysis of doxorubicin accumulation in cell lines from human and rodent cell lines. J Natl Cancer Inst 1989; 81: 55-9.
17. Sakashita A, Kizaki M, Pakkala S, et al. 9-cis retinoic acid: effects on normal and leukemic hematopoiesis in vitro. Blood 1993; 81: 1009-16.
18. Lippman SM, Meyskens FL. Results of the use of vitamin A and retinoids in cutaneous malignancies. Pharmacol Ther 1989; 40: 107-22.
19. Clark RE, Lush CJ, Jacobs A, Smith SA. Effect of 13-cis retinoic acid on survival of patients with myelodysplastic syndrome. Lancet 1987; 1: 763-765.
20. Visani G, Cenacchi A, Tosi P, et al. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report. Br J Haematol 1992; 81: 444-6.
21. Castleberry RP, Emanuel PD, Zuckerman KS, et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994; 331: 1680-4.
22. Miller WH, Jakubowski A, Tong WP, et al. 9-cis retinoic acid induces complete remission but does not reverse clinically acquired retinoid resistance in acute promyelocytic leukemia, Blood 1995; 85: 3021-7.
23. Knobler RM, Trautinger F, Radaszkiewicz T, Kokoschka EM, Micksche M. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991; 24: 247-52.
24. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis retinoic acid and interferon α-2a: effective combination therapy for advanced squamous carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-41.
25. Koller E, Kriegwer O, Kasparu H, Lutz D. Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukemia. Lancet 1991; 338: 1154-5.
26. Venditti A, Stasi R, Del Poeta G, et al. all-trans retinoic acid and low-dose cytosine arabinoside for the treatment of poor prognosis acute myeloid leukemia. Lenkemia 1995; 9: 1121-5.
27. Yang GS, Wang C, Minden MD, McCulloch EA. Fluorescence labeling of nicks in DNA from leukemic blast cells as a measure of damage following cytosine-arabinoside. Application to the study of regulated drug sensitivity. Leukemia 1994; 8: 2052-9.
28. Solan E, Bertrand R, Kohn KW, Pommier Y. Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors. Blood 1993; 81: 1359-68.
29. Chresta CM, Hall BF, Francis GE. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-α is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity. Leukemia 1995; 9: 1373-81.
30. Jing Y, Hashimoto S, Nakajo S, Nakaya K. Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells. Leukemia Res 1994; 18: 299-304.
31. Breitman T, Selonick S, Collins S. Induction of differentiation of the human promyelocytic leukemic cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 1980; 77: 2936-42.
32. Su GMI, Davey RA, Kidman AD. Development of extended multidrug resistance in HL-60 promyelocytic leukaemia cells. Br J Haematol 1994; 88: 566-74.